Peng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peng Wang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Weihong Tan
Department of Biliary-Pancreatic Surgery, Institute of Molecular Medicine (IMM), Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
3 shared publications Fang Zhou
Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Nucleic Acids, Hangzhou Institute of Medicine (HIM)
2 shared publicationsHengxuan Li
Medical School, Faculty of Medicine, Tianjin University, Tianjin 300072, P. R. China
2 shared publicationsXiaodong Li
Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, P. R. China
2 shared publicationsXiaoyi Fu
Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, P. R. China
2 shared publicationsYuenan Shi
Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application
2 shared publications
Latest Publications
- 22 May 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (22) , 16262-16271
Discovery of NMP22-Targeting Aptamers for Point-of-Need Test of Bladder Cancer
Bladder cancer is among the most prevalent urological malignancies worldwide and is associated with high mortality, yet accessible point-of-need testing and large-scale screening strategies remain limited. Nuclear matrix protein 22 (NMP22) is a well-established urinary biomarker for bladder cancer released during tumor development. However, current detection methods suffer from limitations such as inadequate sensitivity, high cost, and lengthy processing times. Herein, we employed SELEX to identify high-affinity aptamers targeting NMP22, aiming to enable broad and convenient screening for bladder cancer. A DNA aptamer, NT2a, with a dissociation constant (Kd) of 24.26 ± 10.47 nM, was identified and employed as the recognition element to develop both lateral-flow immunoassay (LFIA) and enzyme-linked immunosorbent assay (ELISA) platforms. Evaluation in a clinical cohort yielded positive detection rates of 89.47% and 93.75% for LFIA and ELISA, respectively, with both assays demonstrating high specificity, supporting their effectiveness for point-of-need detection of bladder cancer using urine samples. Although NMP22 immunoassays are widely used in clinical practice, aptamer-based technologies are emerging as powerful alternatives, offering enhanced sensitivity and potentially lower cost, particularly for point-of-care, noninvasive surveillance of bladder cancer recurrence.
- 22 May 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (22) , 16262-16271
Discovery of NMP22-Targeting Aptamers for Point-of-Need Test of Bladder Cancer
Bladder cancer is among the most prevalent urological malignancies worldwide and is associated with high mortality, yet accessible point-of-need testing and large-scale screening strategies remain limited. Nuclear matrix protein 22 (NMP22) is a well-established urinary biomarker for bladder cancer released during tumor development. However, current detection methods suffer from limitations such as inadequate sensitivity, high cost, and lengthy processing times. Herein, we employed SELEX to identify high-affinity aptamers targeting NMP22, aiming to enable broad and convenient screening for bladder cancer. A DNA aptamer, NT2a, with a dissociation constant (Kd) of 24.26 ± 10.47 nM, was identified and employed as the recognition element to develop both lateral-flow immunoassay (LFIA) and enzyme-linked immunosorbent assay (ELISA) platforms. Evaluation in a clinical cohort yielded positive detection rates of 89.47% and 93.75% for LFIA and ELISA, respectively, with both assays demonstrating high specificity, supporting their effectiveness for point-of-need detection of bladder cancer using urine samples. Although NMP22 immunoassays are widely used in clinical practice, aptamer-based technologies are emerging as powerful alternatives, offering enhanced sensitivity and potentially lower cost, particularly for point-of-care, noninvasive surveillance of bladder cancer recurrence.
- Open Access
- 17 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1468
Proximity Ligation Assay: From a Foundational Principle to a Versatile Platform for Molecular and Translational Research
The precise analysis of protein interactions in their native cellular context and the sensitive quantification of protein abundance in biological fluids are both fundamental to understanding health and disease. Traditional methods for cellular imaging and biochemical quantification often face limitations in specificity, sensitivity, or the preservation of spatial information. The proximity ligation assay (PLA) is a versatile technological platform developed to overcome these challenges by converting protein recognition events into amplifiable DNA signals, thereby achieving exceptional sensitivity. This foundational principle has given rise to two major formats: in situ PLA (isPLA) and solution-phase PLA. In basic research, isPLA provides high-resolution visualization of protein–protein interactions (PPIs), post-translational modifications (PTMs), and subcellular architecture directly within fixed cells and tissues. In translational and clinical applications, solution-phase PLA enables the highly sensitive quantification of low-abundance biomarkers in liquid samples, which is critical for diagnostics and prognostics in fields such as oncology, neuroscience, and infectious diseases. This review discusses the foundational principles, development, and diverse applications of PLA platforms. We also highlight significant technological advancements, including the development of high-throughput formats, integration with advanced readouts, and the use of alternative affinity reagents. These innovations continue to transform PLA from a targeted validation method into a powerful and multifaceted platform for both fundamental systems biology and clinical diagnostics.
- 17 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1468
Open AccessProximity Ligation Assay: From a Foundational Principle to a Versatile Platform for Molecular and Translational Research
The precise analysis of protein interactions in their native cellular context and the sensitive quantification of protein abundance in biological fluids are both fundamental to understanding health and disease. Traditional methods for cellular imaging and biochemical quantification often face limitations in specificity, sensitivity, or the preservation of spatial information. The proximity ligation assay (PLA) is a versatile technological platform developed to overcome these challenges by converting protein recognition events into amplifiable DNA signals, thereby achieving exceptional sensitivity. This foundational principle has given rise to two major formats: in situ PLA (isPLA) and solution-phase PLA. In basic research, isPLA provides high-resolution visualization of protein–protein interactions (PPIs), post-translational modifications (PTMs), and subcellular architecture directly within fixed cells and tissues. In translational and clinical applications, solution-phase PLA enables the highly sensitive quantification of low-abundance biomarkers in liquid samples, which is critical for diagnostics and prognostics in fields such as oncology, neuroscience, and infectious diseases. This review discusses the foundational principles, development, and diverse applications of PLA platforms. We also highlight significant technological advancements, including the development of high-throughput formats, integration with advanced readouts, and the use of alternative affinity reagents. These innovations continue to transform PLA from a targeted validation method into a powerful and multifaceted platform for both fundamental systems biology and clinical diagnostics.
- 18 April 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 10 (8) , 1575-1596
Research advances in the diagnosis of infectious disease by aptasensor technology
Various aptasensors offer rapid, accurate and reliable detection tools for diagnosis of infectious disease pathogens.
- 18 April 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 10 (8) , 1575-1596
Research advances in the diagnosis of infectious disease by aptasensor technology
Various aptasensors offer rapid, accurate and reliable detection tools for diagnosis of infectious disease pathogens.
- 22 January 2025
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 41 (4) , 2580-2590
Bispecific Aptamer-Drug Conjugates Selectively Eliminate Malignant Hematologic Cells for Treating Acute Myeloid Leukemia
Surface antigen-directed immunotherapy is a curative treatment modality for acute myeloid leukemia (AML) that is characterized by the abundance and stability expression of surface antigens. However, current surface antigen-directed immunotherapies have shown poor outcomes and undesirable mortality rates in treating AML patients, primarily due to acquired resistance that arises from using single-target therapies to address the heterogeneous expression of surface antigens. Hence, in order to improve the efficacy of antigen-specific therapies for treating AML, we designed a bispecific aptamer-drug conjugate. In particular, cell-SELEX incorporating cell lysate-SELEX for aptamers with HEL cells yielded AptCD117, which specifically binds to CD117 (a highly expressed marker on both hematopoietic stem cells and primary AML cells) and has excellent performance in targeting human AML cells. Combined with CD71-binding aptamer LXD-11b (another broadly expressed surface antigen on leukemia cells), bispecific aptamers were designed to couple with monomethyl auristatin F (MMAF) for fabricating aptamer-drug conjugates. Results demonstrated that bispecific aptamer-MMAF conjugates efficiently kill different CD117 and CD71 expression levels of target AML cell lines in vitro. Importantly, the exposure of AML marrow specimens to bispecific aptamer-MMAF conjugates resulted in the selective elimination of primary AML cells in vitro and had no effect on healthy lymphocytes within the same specimens. Thus, these results provide a proof of concept for the generation of bispecific aptamer-drug conjugates directed against human AML cells, which hold the promise of advancing treatment strategies and improving AML patient outcomes.
- 22 January 2025
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 41 (4) , 2580-2590
Bispecific Aptamer-Drug Conjugates Selectively Eliminate Malignant Hematologic Cells for Treating Acute Myeloid Leukemia
Surface antigen-directed immunotherapy is a curative treatment modality for acute myeloid leukemia (AML) that is characterized by the abundance and stability expression of surface antigens. However, current surface antigen-directed immunotherapies have shown poor outcomes and undesirable mortality rates in treating AML patients, primarily due to acquired resistance that arises from using single-target therapies to address the heterogeneous expression of surface antigens. Hence, in order to improve the efficacy of antigen-specific therapies for treating AML, we designed a bispecific aptamer-drug conjugate. In particular, cell-SELEX incorporating cell lysate-SELEX for aptamers with HEL cells yielded AptCD117, which specifically binds to CD117 (a highly expressed marker on both hematopoietic stem cells and primary AML cells) and has excellent performance in targeting human AML cells. Combined with CD71-binding aptamer LXD-11b (another broadly expressed surface antigen on leukemia cells), bispecific aptamers were designed to couple with monomethyl auristatin F (MMAF) for fabricating aptamer-drug conjugates. Results demonstrated that bispecific aptamer-MMAF conjugates efficiently kill different CD117 and CD71 expression levels of target AML cell lines in vitro. Importantly, the exposure of AML marrow specimens to bispecific aptamer-MMAF conjugates resulted in the selective elimination of primary AML cells in vitro and had no effect on healthy lymphocytes within the same specimens. Thus, these results provide a proof of concept for the generation of bispecific aptamer-drug conjugates directed against human AML cells, which hold the promise of advancing treatment strategies and improving AML patient outcomes.
- Top Cited Papers
- 15 January 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (2) , 1032-1042
Hypochlorous Acid-Activatable NIR Fluorescence/Photoacoustic Dual-Modal Probe with High Signal-to-Background Ratios for Imaging of Liver Injury and Plasma Diagnosis of Sepsis
Hypochlorous acid can be employed as a biomarker for blood infection (such as sepsis) and tissue damage (such as drug-induced liver injury, DILI), and the diagnosis of tissue damage or blood infection can be achieved through the detection of hypochlorous acid in relevant biological samples. Considering the complex environment and the diverse interferences in living organisms and blood plasma, developing new detection methods for HClO with high signal-to-background ratios is particularly important, and it can improve the accuracy of detection and quality of imaging based on a higher contrast, which makes the detection of HClO clearer and more accurate. Here, based on the advantages of the NIR fluorescence/photoacoustic dual-modal probe, we reported a hypochlorous acid-activatable NIR fluorescence/photoacoustic dual-modal probe (NIRF-PA-HClO) based on the spirolactam ring-opening strategy in this paper. NIRF-PA-HClO showed excellent NIRF/PA dual-modal responses with high SBRs for HClO in solution, cells, and mice. Moreover, NIRF-PA-HClO was successfully applied for high-contrast imaging of DILI. Finally, NIRF-PA-HClO was employed for the blood plasma diagnosis of sepsis with satisfactory results. In summary, the above results proved that NIRF-PA-HClO would be a potentially useful tool for the study of physiological and pathological roles of HClO, the investigation of the pathology and therapeutic mechanisms of hepatotoxicity, and the diagnosis of blood infection. Also, the development of NIRF-PA-HClO provides new design mentality for constructing other analyte-activatable NIRF/PA dual-modal probes with high SBRs.
- 15 January 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (2) , 1032-1042
Top Cited PapersHypochlorous Acid-Activatable NIR Fluorescence/Photoacoustic Dual-Modal Probe with High Signal-to-Background Ratios for Imaging of Liver Injury and Plasma Diagnosis of Sepsis
Hypochlorous acid can be employed as a biomarker for blood infection (such as sepsis) and tissue damage (such as drug-induced liver injury, DILI), and the diagnosis of tissue damage or blood infection can be achieved through the detection of hypochlorous acid in relevant biological samples. Considering the complex environment and the diverse interferences in living organisms and blood plasma, developing new detection methods for HClO with high signal-to-background ratios is particularly important, and it can improve the accuracy of detection and quality of imaging based on a higher contrast, which makes the detection of HClO clearer and more accurate. Here, based on the advantages of the NIR fluorescence/photoacoustic dual-modal probe, we reported a hypochlorous acid-activatable NIR fluorescence/photoacoustic dual-modal probe (NIRF-PA-HClO) based on the spirolactam ring-opening strategy in this paper. NIRF-PA-HClO showed excellent NIRF/PA dual-modal responses with high SBRs for HClO in solution, cells, and mice. Moreover, NIRF-PA-HClO was successfully applied for high-contrast imaging of DILI. Finally, NIRF-PA-HClO was employed for the blood plasma diagnosis of sepsis with satisfactory results. In summary, the above results proved that NIRF-PA-HClO would be a potentially useful tool for the study of physiological and pathological roles of HClO, the investigation of the pathology and therapeutic mechanisms of hepatotoxicity, and the diagnosis of blood infection. Also, the development of NIRF-PA-HClO provides new design mentality for constructing other analyte-activatable NIRF/PA dual-modal probes with high SBRs.
- 5 December 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (5) , 1681-1689
Multiple aptamer recognition-based quantum dot lateral flow platform: ultrasensitive point-of-care testing of respiratory infectious diseases
Respiratory infectious diseases spread rapidly and have a wide range of impacts, posing a serious threat to public health security. The development of a sensitive, accurate, and rapid detection method for respiratory viruses is crucial for disease prevention and control. However, existing methods are inadequate in satisfying the demand for accurate and convenient detection simultaneously. Therefore, an ultrasensitive point-of-care testing (POCT) platform based on a multiple aptamer recognition-based quantum dot lateral flow immunoassay (MARQ-LFIA) was developed in this work. This platform consisted of multiple high-affinity aptamers for recognizing different sites on a respiratory infectious virus protein, enhancing the efficiency of virus identification in complex environments. By combining a multiple aptamer recognition strategy with quantum dot fluorescent technique to construct LFIA test strips and pairing them with a high-gain portable fluorescence reader, excellent detection sensitivity and specificity were achieved in the case of coronavirus disease 2019 (COVID-19). The limits of detection were 1.427 pg mL−1 and 1643 U mL−1 towards the nucleocapsid protein and inactivated viruses, respectively, indicating that MARQ-LFIA improved detection sensitivity compared to reported methods. More critically, by testing thirty COVID-19 positive and twenty negative patient samples, the positive detection rate increased from 55.17% to 86.67% compared with commercially similar products. The universality of MARQ-LFIA was also investigated for diagnosing influenza B. We believe that MARQ-LFIA can be a promising POCT tool with potential applications in the areas of public health for the growing demand for precision diagnosis and treatment.
- 5 December 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (5) , 1681-1689
Multiple aptamer recognition-based quantum dot lateral flow platform: ultrasensitive point-of-care testing of respiratory infectious diseases
Respiratory infectious diseases spread rapidly and have a wide range of impacts, posing a serious threat to public health security. The development of a sensitive, accurate, and rapid detection method for respiratory viruses is crucial for disease prevention and control. However, existing methods are inadequate in satisfying the demand for accurate and convenient detection simultaneously. Therefore, an ultrasensitive point-of-care testing (POCT) platform based on a multiple aptamer recognition-based quantum dot lateral flow immunoassay (MARQ-LFIA) was developed in this work. This platform consisted of multiple high-affinity aptamers for recognizing different sites on a respiratory infectious virus protein, enhancing the efficiency of virus identification in complex environments. By combining a multiple aptamer recognition strategy with quantum dot fluorescent technique to construct LFIA test strips and pairing them with a high-gain portable fluorescence reader, excellent detection sensitivity and specificity were achieved in the case of coronavirus disease 2019 (COVID-19). The limits of detection were 1.427 pg mL−1 and 1643 U mL−1 towards the nucleocapsid protein and inactivated viruses, respectively, indicating that MARQ-LFIA improved detection sensitivity compared to reported methods. More critically, by testing thirty COVID-19 positive and twenty negative patient samples, the positive detection rate increased from 55.17% to 86.67% compared with commercially similar products. The universality of MARQ-LFIA was also investigated for diagnosing influenza B. We believe that MARQ-LFIA can be a promising POCT tool with potential applications in the areas of public health for the growing demand for precision diagnosis and treatment.
- 2 September 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (79) , 11107-11110
COF-based nanoreactors for click-activated prodrug delivery and precise anti-vascular therapy
Herein, we report a new click-activated prodrug, CA4V, and a bioorthogonal nanoreactor, CA4V/ZIF-90@TzCOF@Apt, which consists of a ZIF-90 core, tetrazine-based covalent organic framework (COF) shells and an aptamer polymer coating. When targeting a tumor, the acid-causing collapse of ZIF-90 initiates a nanoconfined bioorthogonal reaction in defined COF cages, which boosts the click efficiency of CA4V activation and therapeutic effects in vivo.
- 2 September 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 58 (79) , 11107-11110
COF-based nanoreactors for click-activated prodrug delivery and precise anti-vascular therapy
Herein, we report a new click-activated prodrug, CA4V, and a bioorthogonal nanoreactor, CA4V/ZIF-90@TzCOF@Apt, which consists of a ZIF-90 core, tetrazine-based covalent organic framework (COF) shells and an aptamer polymer coating. When targeting a tumor, the acid-causing collapse of ZIF-90 initiates a nanoconfined bioorthogonal reaction in defined COF cages, which boosts the click efficiency of CA4V activation and therapeutic effects in vivo.
- 8 May 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (44) , 6033-6036
Taurine-modified Ru(ii)-complex targets cancerous brain cells for photodynamic therapy
Symmetrical taurine modification not only enhances the intracellular affinity of a polypyridyl Ru-complex to cancer cells, but also boosts the quantum yield in a pH-independent manner without sacrificing water solubility for cytosolic photosensitizers of photodynamic therapy, with prominent efficacy in cancerous brain cells.
- 8 May 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (44) , 6033-6036
Taurine-modified Ru(ii)-complex targets cancerous brain cells for photodynamic therapy
Symmetrical taurine modification not only enhances the intracellular affinity of a polypyridyl Ru-complex to cancer cells, but also boosts the quantum yield in a pH-independent manner without sacrificing water solubility for cytosolic photosensitizers of photodynamic therapy, with prominent efficacy in cancerous brain cells.
- 22 February 2014
- Published by Springer Nature in Biotechnology Letters
- Vol. 36 (6) , 1203-1207
Synthesis of a near-infrared fluorescent probe and its application in imaging of MCF-7 cells
IR-789, a novel near-infrared fluorescent probe, was designed, synthesized, and applied to living cells. The probe exhibited better response fluorescence characteristics than the only FDA-approved agent, indocyanine green. Cell experiments showed that the probe had high affinity and without apparent cytotoxicity. Fluorescent image experiments in living MCF-7 cells (human breast adenocarcinoma cell line) further demonstrated the potential applications of the probe in biological systems. The probe effectively prevented the influence of autofluorescence and native cellular species in biological systems. It also exhibited high sensitivity, good photostability, and excellent cell membrane permeability.
- 22 February 2014
- Published by Springer Nature in Biotechnology Letters
- Vol. 36 (6) , 1203-1207
Synthesis of a near-infrared fluorescent probe and its application in imaging of MCF-7 cells
IR-789, a novel near-infrared fluorescent probe, was designed, synthesized, and applied to living cells. The probe exhibited better response fluorescence characteristics than the only FDA-approved agent, indocyanine green. Cell experiments showed that the probe had high affinity and without apparent cytotoxicity. Fluorescent image experiments in living MCF-7 cells (human breast adenocarcinoma cell line) further demonstrated the potential applications of the probe in biological systems. The probe effectively prevented the influence of autofluorescence and native cellular species in biological systems. It also exhibited high sensitivity, good photostability, and excellent cell membrane permeability.